[双特异性和多特异性抗体药物的差异性发现策略]
Dong Li1,2
1RemeGen Co., Ltd., Yantai 264006, Shandong, China.
Sheng wu gong cheng xue bao = Chinese journal of biotechnology
|November 25, 2024
概括
双特异性抗体药物比单克隆抗体提供了更好的疗效和安全性,代表了新一代治疗方法. 本综述涵盖了它们的开发,应用和创新药物发现策略,增强临床治疗选择.
科学领域:
- 生物技术是生物技术.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与传统单克隆抗体疗法相比,双特异性抗体药物显示出更高的疗效和安全性.
- 由于基因工程的发展和工业成熟度,该领域正在迅速发展.
- 不断扩大的适应症突出显示了它们日益增长的临床价值和潜力.
研究的目的:
- 提供对双特异性和多特异性抗体药物的全面审查.
- 讨论它们的发展阶段,指示,目标组合,结构格式和机制.
- 概述差异化药物发现和临床转化策略.
主要方法:
- 对双特异性和多特异性抗体药物开发的文献综述.
- 分析当前和新兴的临床应用.
- 检查结构格式和作用的潜在机制.
主要成果:
- 双特异性抗体正在成为新一代有效疗法的新一代.
- 在了解它们的发展,准和机制方面取得了重大进展.
- 该审查确定了促进差异化两种特定药物发现的关键策略.
结论:
- 双特异性和多特异性抗体提供了更精确和更有效的治疗选择.
- 进一步的研究和开发将促进它们的临床转化,并扩大治疗应用.
- 这些先进的疗法已准备好满足日益增长的临床需求,并创造显著的临床价值.
相关概念视频
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K


